Celltrion, Inc. Celltrion, Inc.

Celltrion, Inc.

068270

Rang in aandelen #720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Aandeelprijs
$146.63
Marktkapitalisatie
$33.44B
Verandering (1 dag)
-1.52%
Verandering (1 jaar)
23.60%
Land
KR
Handel Celltrion, Inc. (068270)

Categorie

Healthcare
Aandelsplitsingen voor Celltrion, Inc. (068270)
Het aandeel Celltrion, Inc. (symbool: 068270) heeft in totaal 17 splitsingen ondergaan.
De meest recente splitsing vond plaats op Jun 04, 2026.
Eén aandeel 068270 dat vóór Aug 21, 2006 werd gekocht, staat nu gelijk aan 1.6182173250826 aandelen 068270.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
2026-06-04 21:20 x1.05 x1.6182173250826
2024-12-27 21:20 x1.05 x1.5411593572216
2022-12-28 26:25 x1.04 x1.4677708164015
2021-12-29 51:50 x1.02 x1.4113180926937
2020-12-29 51:50 x1.02 x1.3836451889154
2019-12-27 21:20 x1.05 x1.3565148910936
2018-12-27 51:50 x1.02 x1.2919189438986
2017-12-27 51:50 x1.02 x1.2665871999006
2016-12-28 21:20 x1.05 x1.2417521567653
2015-12-29 103:100 x1.03 x1.1826211016813
2014-12-29 21:20 x1.05 x1.148175826875
2013-12-27 103:100 x1.03 x1.0935007875
2013-03-04 1:2 x0.5 x1.06165125
2012-12-27 23:20 x1.15 x2.1233025
2012-05-24 3:2 x1.5 x1.84635
2006-09-28 1119:1000 x1.119 x1.2309
2006-08-21 11:10 x1.1 x1.1
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 1 x100
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL